

For more information:

Susan Wright
Stephens & Associates Advertising
susan.wright@stephens-adv.com
913.213.6819

**ELIAS Animal Health Adds Clinical Trial Site for ECI™
for the Treatment of Canine Osteosarcoma**

*Joins parent company, TVAX Biomedical, for One Health Day presentation
on cancer advancements for people and pets during Collaborate2Cure series*

Olathe, Kan., Nov. 15, 2016 – [ELIAS Animal Health](#), a clinical stage development company advancing novel treatments for cancer in companion animals, is offering a fourth site for its clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™) as a treatment for newly-diagnosed appendicular osteosarcoma in dogs.

The objective of this clinical trial is to determine whether ECI™ used in combination with surgery produces better outcomes than treatment with surgery alone. Efficacy will be determined by patient survival and comparing the outcomes to historical control data. The trial will be conducted at the Veterinary Specialty Hospital of San Diego.

ELIAS Animal Health chief executive officer, Tammie Wahaus, shared a promising update on trial results to-date on Nov. 3, during the [Collaborate2Cure](#) series sponsored by [Kansas City Area Life Sciences Institute](#) and BioKansas.

“Early clinical study results already show positive outcomes,” said Wahaus. “One patient, a 6-year old German Shorthaired Pointer, has survived one year after her osteosarcoma diagnosis, which is twice as long as the typical prognosis. At her most recent follow-up visit, lung radiographs showed no signs of metastasis and she was a happy, energetic amputee. Her results are consistent with the results achieved in other preclinical and clinical studies of this treatment platform.”

ELIAS Animal Health and parent company, [TVAX Biomedical, Inc.](#), which developed the unique immunotherapy treatment platform for use in humans known as TVAX Immunotherapy®, were invited to present during the Collaborate2Cure series, which is aimed at stimulating collaboration across the Midwest and solving specific scientific challenges.

In her special [One Health](#) Day [presentation](#), she explained how TVAX and ELIAS are jointly advancing this personalized treatment that triggers the patient’s immune system to attack and eliminate cancer cells. New collaborations for two multi-site brain cancer studies in children and adults are planned in the near future.

-more-

“Each patient’s cancer is unique and the ECI platform offers a genetically-unique approach that could be useful in treating numerous types of cancer at any stage of disease,” Wahaus said. “The ECI approach is a proprietary combination of pretreatment with a personalized cancer vaccination followed by ex vivo activated “killer” T-cell therapy. This dual approach is what makes the ECI approach distinct from other cancer immunotherapies and offers the promise of improved disease survival outcomes and better quality of life for cancer patients.”

Current ELIAS Animal Health Canine Clinical Trials Accepting Enrollments

Trial type	Clinical Trial Site	Cancer indication	Enrollment Contact
Combination of chemotherapy and ECI™ therapy to treat newly diagnosed B-cell lymphoma in dogs	Kansas State University – Veterinary Health Center, Manhattan, Kan.	Newly-diagnosed B cell lymphoma	Misty Bear, clinicaltrials@vet.ksu.edu
Combination of surgery and ECI™ therapy to treat newly diagnosed osteosarcoma in dogs	Veterinary Specialty Hospital of San Diego, Calif.	Newly-diagnosed appendicular osteosarcoma	Dr. Brenda Phillips, medical.oncology@vshsd.com
	University of Missouri – Veterinary Health Center, Columbia, Mo.	Newly-diagnosed appendicular osteosarcoma	Debbie Tate, tated@missouri.edu
Both trial types	Bellingham Veterinary Critical Care, Bellingham, Wash.	Osteosarcoma, B-cell lymphoma, other cancers	Dr. Ed Sullivan, Dr. Theresa Westfall, bvcc720@yahoo.com

Pet owners or veterinarians interested in more information or participating in these clinical trials can visit www.eliasanimalhealth.com or request more information from clinicaltrials@eliasah.com.

About ELIAS Animal Health

Based in Olathe, Kan., ELIAS Animal Health is a medical biotechnology company advancing its novel targeted T cell-based immunotherapy for the treatment of cancer in the veterinary sector. Its initial focus is on cancer in dogs. Additional clinical studies for the treatment of cancer in horses and cats may be initiated in the future. The company’s novel therapeutic approach offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is treated. For more information, please visit www.eliasanimalhealth.com.

FOR IMMEDIATE RELEASE

About TVAX

TVAX Biomedical is a clinical stage development company advancing its novel targeted cell-based immunotherapy for the treatment of cancer. Current treatment options for cancer, which include surgery, radiation and/or chemotherapy, are not adequately meeting patient treatment needs. Radiation and chemotherapy in particular are highly toxic and rarely “cure” the patient by permanently eliminating the cancer. With more than 1.5 million new cases of cancer diagnosed and more than 500,000 cancer deaths in the U.S. each year, more effective, less toxic treatment options are desperately needed. For more information, please visit www.tvaxbiomedical.com.

###